North America Vulvovaginal Candidiasis Treatment Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration (Oral, Intravenous and Topical), By Drug Class, By Country and Growth Forecast, 2022

List of Tables

The North America Vulvovaginal Candidiasis Treatment Market would witness market growth of 3.9% CAGR during the forecast period (2022-2028).

The vaginal cultures should be performed for the women with negative results but have symptoms of VVC and proper treatment is required for those with positive results. Empiric treatment is considered appropriate if candida cultures cannot be performed. Most of the PCR tests for yeasts are not approved by FDA, because of this, the providers should be familiar with the performance characteristics of the test they are using.

Recurring VVC condition, which is defined as three or more episodes of having VVC symptoms in a year, affects more the 5% of women which also causes a substantial economic concern. Recurrence of vulvovaginal candidiasis could be idiopathic or secondary that is related to continuing diabetes, antibiotic use, or other such factors.

In most cases, recurrent VVC that is caused by C. Albicans could be treated by short-duration oral and topical azole therapies. Although to maintain clinical & mycologic control longer duration of initial therapy is suggested by gynecologists. An example of longer duration therapy is either 7-14 days of topical therapy or an oral dose of 100 mg, 150-mg, and 200 mg of fluconazole every third day three times which mean day 1, 4, and 7.

The risk of women with HIV infection risk of vulvovaginal candidiasis is high. Women with HIV are more prevalent to have white adherent vaginal discharge, mucosal itching & burning. Furthermore, women with advanced immunosuppression could have VVC severe and recurrent episodes of VVC. As a result of the high prevalence of HIV in the region, the market for vulvovaginal candidiasis treatment will expand during the forecast period.

The US market dominated the North America Vulvovaginal Candidiasis Treatment Market by Country in 2021; thereby, achieving a market value of $345.8 million by 2028. The Canada market is experiencing a CAGR of 6.3% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 5.4% during (2022 - 2028).

Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Route of Administration, the market is segmented into Oral, Intravenous and Topical. Based on Drug Class, the market is segmented into Fluconazole, Clotrimazole, Terconazole, Terbinafine, Nystatin, Ketoconazole and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Bristol Myers Squibb Company, Pfizer, Inc., Astellas Pharma, Inc., Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC), Basilea Pharmaceutica Ltd., Scynexis, Inc. and Grupo Ferrer Internacional S.A.

Scope of the Study

Market Segments covered in the Report:

By Distribution Channel

Retail Pharmacy
Hospital Pharmacy
Online Pharmacy

By Route of Administration

Oral
Intravenous
Topical

By Drug Class

Fluconazole
Clotrimazole
Terconazole
Terbinafine
Nystatin
Ketoconazole
Others

By Country

US
Canada
Mexico
Rest of North America

Companies Profiled

Bayer AG
Bristol Myers Squibb Company
Pfizer, Inc.
Astellas Pharma, Inc.
Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC)
Basilea Pharmaceutica Ltd.
Scynexis, Inc.
Grupo Ferrer Internacional S.A.

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 North America Vulvovaginal Candidiasis Treatment Market, by Distribution Channel
- 1.4.2 North America Vulvovaginal Candidiasis Treatment Market, by Route of Administration
- 1.4.3 North America Vulvovaginal Candidiasis Treatment Market, by Drug Class
- 1.4.4 North America Vulvovaginal Candidiasis Treatment Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview

2.1 Introduction
- 2.1.1 Overview
  - 2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints

Chapter 3. North America Vulvovaginal Candidiasis Treatment Market by Distribution Channel

3.1 North America Retail Pharmacy Market by Country
3.2 North America Hospital Pharmacy Market by Country
3.3 North America Online Pharmacy Market by Country

Chapter 4. North America Vulvovaginal Candidiasis Treatment Market by Route of Administration

4.1 North America Oral Market by Country
4.2 North America Intravenous Market by Country
4.3 North America Topical Market by Country

Chapter 5. North America Vulvovaginal Candidiasis Treatment Market by Drug Class

5.1 North America Fluconazole Market by Country
5.2 North America Clotrimazole Market by Country
5.3 North America Terconazole Market by Country
5.4 North America Terbinafine Market by Country
5.5 North America Nystatin Market by Country
5.6 North America Ketoconazole Market by Country
5.7 North America Others Market by Country

Chapter 6. North America Vulvovaginal Candidiasis Treatment Market by Country

6.1 US Vulvovaginal Candidiasis Treatment Market
- 6.1.1 US Vulvovaginal Candidiasis Treatment Market by Distribution Channel
- 6.1.2 US Vulvovaginal Candidiasis Treatment Market by Route of Administration
- 6.1.3 US Vulvovaginal Candidiasis Treatment Market by Drug Class
6.2 Canada Vulvovaginal Candidiasis Treatment Market
- 6.2.1 Canada Vulvovaginal Candidiasis Treatment Market by Distribution Channel
- 6.2.2 Canada Vulvovaginal Candidiasis Treatment Market by Route of Administration
- 6.2.3 Canada Vulvovaginal Candidiasis Treatment Market by Drug Class
6.3 Mexico Vulvovaginal Candidiasis Treatment Market
- 6.3.1 Mexico Vulvovaginal Candidiasis Treatment Market by Distribution Channel
- 6.3.2 Mexico Vulvovaginal Candidiasis Treatment Market by Route of Administration
- 6.3.3 Mexico Vulvovaginal Candidiasis Treatment Market by Drug Class
6.4 Rest of North America Vulvovaginal Candidiasis Treatment Market
- 6.4.1 Rest of North America Vulvovaginal Candidiasis Treatment Market by Distribution Channel
- 6.4.2 Rest of North America Vulvovaginal Candidiasis Treatment Market by Route of Administration
- 6.4.3 Rest of North America Vulvovaginal Candidiasis Treatment Market by Drug Class

Chapter 7. Company Profiles

7.1 Bayer AG
- 7.1.1 Company Overview
- 7.1.2 Financial Analysis
- 7.1.3 Segmental and Regional Analysis
- 7.1.4 Research & Development Expense
7.2 Pfizer, Inc.
- 7.2.1 Company Overview
- 7.2.2 Financial Analysis
- 7.2.3 Regional & Segmental Analysis
- 7.2.4 Research & Development Expense
7.3 Bristol Myers Squibb Company
- 7.3.1 Company Overview
- 7.3.2 Financial Analysis
- 7.3.3 Regional Analysis
- 7.3.4 Research & Development Expenses
7.4 Astellas Pharma, Inc.
- 7.4.1 Company Overview
- 7.4.2 Financial Analysis
- 7.4.3 Regional Analysis
- 7.4.4 Research & Development Expense
7.5 Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management, LLC)
- 7.5.1 Company Overview
- 7.5.2 Recent strategies and developments:
  - 7.5.2.1 Trials and Approvals:
7.6 Basilea Pharmaceutica Ltd.
- 7.6.1 Company Overview
- 7.6.2 Financial Analysis
- 7.6.3 Segmental and Regional Analysis
- 7.6.4 Research & Development Expenses
7.7 Scynexis, Inc.
- 7.7.1 Company Overview
- 7.7.2 Financial Analysis
- 7.7.3 Research & Development Expenses
- 7.7.4 Recent strategies and developments:
  - 7.7.4.1 Trials and Approvals:
7.8 Grupo Ferrer Internacional S.A.
- 7.8.1 Company Overview

LIST OF TABLES

TABLE 1 North America Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 2 North America Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 3 North America Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 4 North America Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 5 North America Retail Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 6 North America Retail Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 7 North America Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 8 North America Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 9 North America Online Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 10 North America Online Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 11 North America Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 12 North America Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 13 North America Oral Market by Country, 2018 - 2021, USD Million
TABLE 14 North America Oral Market by Country, 2022 - 2028, USD Million
TABLE 15 North America Intravenous Market by Country, 2018 - 2021, USD Million
TABLE 16 North America Intravenous Market by Country, 2022 - 2028, USD Million
TABLE 17 North America Topical Market by Country, 2018 - 2021, USD Million
TABLE 18 North America Topical Market by Country, 2022 - 2028, USD Million
TABLE 19 North America Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 20 North America Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 21 North America Fluconazole Market by Country, 2018 - 2021, USD Million
TABLE 22 North America Fluconazole Market by Country, 2022 - 2028, USD Million
TABLE 23 North America Clotrimazole Market by Country, 2018 - 2021, USD Million
TABLE 24 North America Clotrimazole Market by Country, 2022 - 2028, USD Million
TABLE 25 North America Terconazole Market by Country, 2018 - 2021, USD Million
TABLE 26 North America Terconazole Market by Country, 2022 - 2028, USD Million
TABLE 27 North America Terbinafine Market by Country, 2018 - 2021, USD Million
TABLE 28 North America Terbinafine Market by Country, 2022 - 2028, USD Million
TABLE 29 North America Nystatin Market by Country, 2018 - 2021, USD Million
TABLE 30 North America Nystatin Market by Country, 2022 - 2028, USD Million
TABLE 31 North America Ketoconazole Market by Country, 2018 - 2021, USD Million
TABLE 32 North America Ketoconazole Market by Country, 2022 - 2028, USD Million
TABLE 33 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 34 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 35 North America Vulvovaginal Candidiasis Treatment Market by Country, 2018 - 2021, USD Million
TABLE 36 North America Vulvovaginal Candidiasis Treatment Market by Country, 2022 - 2028, USD Million
TABLE 37 US Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 38 US Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 39 US Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 40 US Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 41 US Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 42 US Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 43 US Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 44 US Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 45 Canada Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 46 Canada Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 47 Canada Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 48 Canada Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 49 Canada Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 50 Canada Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 51 Canada Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 52 Canada Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 53 Mexico Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 54 Mexico Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 55 Mexico Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 56 Mexico Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 57 Mexico Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 58 Mexico Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 59 Mexico Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 60 Mexico Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 61 Rest of North America Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 62 Rest of North America Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 63 Rest of North America Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 64 Rest of North America Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 65 Rest of North America Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 66 Rest of North America Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 67 Rest of North America Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 68 Rest of North America Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 69 Key Information - Bayer AG
TABLE 70 Key Information - Pfizer, Inc.
TABLE 71 Key Information - Bristol Myers Squibb Company
TABLE 72 key information - Astellas Pharma, Inc.
TABLE 73 Key Information - Mycovia Pharmaceuticals, Inc.
TABLE 74 Key Information - Basilea Pharmaceutica Ltd.
TABLE 75 Key Information - Scynexis, Inc.
TABLE 76 Key Information - Grupo Ferrer Internacional S.A.

List of Figures

FIG 1 Methodology for the research

North America Vulvovaginal Candidiasis Treatment Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration (Oral, Intravenous and Topical), By Drug Class, By Country and Growth Forecast, 2022 - 2028

Description

Table of Contents